US Federal Register Drops Alibaba Qwen AI Search Tool 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
SoftBank Launches $11 Billion Bond Sale to Fund OpenAI Investment 
Allegro Raises 2026 Outlook as International GMV Surges 
SpaceX Nasdaq 100 Weight to More Than Double in Rebalance 
Volkswagen Shares Slide After 2026 Profit Outlook Cut 
OpenAI Urges US-Led Global Standards for Frontier AI 
FCC Approves Foreign Investment in $110B Paramount-Warner Bros. Deal 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
Hyundai CEO Warns Chinese Automakers Could Disrupt US Market 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Trump Plans Federal AI Force and AI Czar 
Prysmian, Rio Tinto Supply Low-Carbon Cables for Amazon Ohio Data Center 
CNN, MS NOW and Politico Sue Trump Over White House Media Ban 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Add as a preferred source on Google
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
